Literature DB >> 24478402

Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance.

Manuel Buscarlet1, Veneta Krasteva, Lena Ho, Camille Simon, Josée Hébert, Brian Wilhelm, Gerald R Crabtree, Guy Sauvageau, Pierre Thibault, Julie A Lessard.   

Abstract

In mammals, combinatorial assembly of alternative families of subunits confers functional specificity to adenosine triphosphate (ATP)-dependent SWI/SNF-like Brg/Brm-associated factor (BAF) chromatin remodeling complexes by creating distinct polymorphic surfaces for interaction with regulatory elements and DNA-binding factors. Although redundant in terms of biochemical activity, the core ATPase subunits, BRG/SMARCA4 and BRM/SMARCA2, are functionally distinct and may contribute to complex specificity. Here we show using quantitative proteomics that BAF complexes expressed in leukemia are specifically assembled around the BRG ATPase. Moreover, using a mouse model of acute myeloid leukemia, we demonstrate that BRG is essential for leukemia maintenance, as leukemic cells lacking BRG rapidly undergo cell-cycle arrest and apoptosis. Most importantly, we show that BRG is dispensable for the maintenance of immunophenotypic long-term repopulating hematopoietic stem cells, suggesting that adroit targeting of BRG in leukemia may have potent and specific therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24478402      PMCID: PMC3954053          DOI: 10.1182/blood-2013-02-483495

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Growth inhibition by the mammalian SWI-SNF subunit Brm is regulated by acetylation.

Authors:  Brigitte Bourachot; Moshe Yaniv; Christian Muchardt
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

2.  Brg1, the ATPase subunit of the SWI/SNF chromatin remodeling complex, is required for myeloid differentiation to granulocytes.

Authors:  Diana Vradii; Stefan Wagner; Diem N Doan; Jeffrey A Nickerson; Martin Montecino; Jane B Lian; Janet L Stein; Andre J van Wijnen; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2006-01       Impact factor: 6.384

3.  ras transformation is associated with decreased expression of the brm/SNF2alpha ATPase from the mammalian SWI-SNF complex.

Authors:  C Muchardt; B Bourachot; J C Reyes; M Yaniv
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

4.  A Brg1 mutation that uncouples ATPase activity from chromatin remodeling reveals an essential role for SWI/SNF-related complexes in beta-globin expression and erythroid development.

Authors:  Scott J Bultman; Thomas C Gebuhr; Terry Magnuson
Journal:  Genes Dev       Date:  2005-11-14       Impact factor: 11.361

5.  Temporally controlled targeted somatic mutagenesis in embryonic surface ectoderm and fetal epidermal keratinocytes unveils two distinct developmental functions of BRG1 in limb morphogenesis and skin barrier formation.

Authors:  Arup Kumar Indra; Valérie Dupé; Jean-Marc Bornert; Nadia Messaddeq; Moshe Yaniv; Manuel Mark; Pierre Chambon; Daniel Metzger
Journal:  Development       Date:  2005-10       Impact factor: 6.868

6.  Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits.

Authors:  M L Phelan; S Sif; G J Narlikar; R E Kingston
Journal:  Mol Cell       Date:  1999-02       Impact factor: 17.970

7.  Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia.

Authors:  F Grand; S Kulkarni; A Chase; J M Goldman; M Gordon; N C Cross
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

8.  Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha).

Authors:  J C Reyes; J Barra; C Muchardt; A Camus; C Babinet; M Yaniv
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

9.  Cyclin A repression in quiescent cells is associated with chromatin remodeling of its promoter and requires Brahma/SNF2alpha.

Authors:  Marjorie Coisy; Virginie Roure; Magali Ribot; Alexandre Philips; Christian Muchardt; Jean-Marie Blanchard; Jean-Christophe Dantonel
Journal:  Mol Cell       Date:  2004-07-02       Impact factor: 17.970

10.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

View more
  49 in total

1.  Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes.

Authors:  Maximilian Witzel; Daniel Petersheim; Yanxin Fan; Ehsan Bahrami; Tomas Racek; Meino Rohlfs; Jacek Puchałka; Christian Mertes; Julien Gagneur; Christoph Ziegenhain; Wolfgang Enard; Asbjørg Stray-Pedersen; Peter D Arkwright; Miguel R Abboud; Vahid Pazhakh; Graham J Lieschke; Peter M Krawitz; Maik Dahlhoff; Marlon R Schneider; Eckhard Wolf; Hans-Peter Horny; Heinrich Schmidt; Alejandro A Schäffer; Christoph Klein
Journal:  Nat Genet       Date:  2017-04-03       Impact factor: 38.330

2.  Novel Interactions between the Human T-Cell Leukemia Virus Type 1 Antisense Protein HBZ and the SWI/SNF Chromatin Remodeling Family: Implications for Viral Life Cycle.

Authors:  Ahlam Alasiri; Jorge Abboud Guerr; William W Hall; Noreen Sheehy
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

3.  The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Authors:  Thomas A Paul; Parantu K Shah; Bhavatarini Vangamudi; Maria Kost-Alimova; Lisa Nottebaum; Xi Shi; Yanai Zhan; Elisabetta Leo; Harshad S Mahadeshwar; Alexei Protopopov; Andrew Futreal; Trang N Tieu; Mike Peoples; Timothy P Heffernan; Joseph R Marszalek; Carlo Toniatti; Alessia Petrocchi; Dominique Verhelle; Dafydd R Owen; Giulio Draetta; Philip Jones; Wylie S Palmer; Shikhar Sharma; Jannik N Andersen
Journal:  Cancer Res       Date:  2015-07-02       Impact factor: 12.701

4.  BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.

Authors:  M Cuadros; V Sánchez-Martín; A Herrera; C Baliñas; J Martín-Padrón; L Boyero; P Peinado; P P Medina
Journal:  Clin Transl Oncol       Date:  2017-03-01       Impact factor: 3.405

5.  The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation.

Authors:  Qiong Wu; Pasil Madany; Jacqueline Akech; Jason R Dobson; Stephen Douthwright; Gillian Browne; Jennifer L Colby; Georg E Winter; James E Bradner; Jitesh Pratap; Greenfield Sluder; Rohit Bhargava; Simion I Chiosea; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian; Jeffrey A Nickerson; Anthony N Imbalzano
Journal:  J Cell Physiol       Date:  2015-11       Impact factor: 6.384

Review 6.  A rationale to target the SWI/SNF complex for cancer therapy.

Authors:  Anja F Hohmann; Christopher R Vakoc
Journal:  Trends Genet       Date:  2014-06-03       Impact factor: 11.639

7.  BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.

Authors:  L Jubierre; A Soriano; L Planells-Ferrer; L París-Coderch; S P Tenbaum; O A Romero; R S Moubarak; A Almazán-Moga; C Molist; J Roma; S Navarro; R Noguera; M Sánchez-Céspedes; J X Comella; H G Palmer; J Sánchez de Toledo; S Gallego; M F Segura
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

Review 8.  Chromatin regulation and dynamics in stem cells.

Authors:  David C Klein; Sarah J Hainer
Journal:  Curr Top Dev Biol       Date:  2019-12-30       Impact factor: 4.897

Review 9.  Vulnerabilities of mutant SWI/SNF complexes in cancer.

Authors:  Katherine C Helming; Xiaofeng Wang; Charles W M Roberts
Journal:  Cancer Cell       Date:  2014-09-08       Impact factor: 31.743

10.  A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.

Authors:  H Sakai; N Hosono; H Nakazawa; B Przychodzen; C Polprasert; H E Carraway; M A Sekeres; T Radivoyevitch; K Yoshida; M Sanada; T Yoshizato; K Kataoka; M M Nakagawa; H Ueno; Y Nannya; A Kon; Y Shiozawa; J Takeda; Y Shiraishi; K Chiba; S Miyano; J Singh; R A Padgett; S Ogawa; J P Maciejewski; H Makishima
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.